Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Phase 3 Active, not recruiting NCT01892722

Condition	Multiple Sclerosis
Phase	Phase 3
Sponsor	Novartis Pharmaceuticals
Status	Active, not recruiting
Enrollment	240 participants
Interventions	Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Start date	Jul 26, 2013
Completion date	Jul 14, 2017
Results posted	Sep 19, 2018

Summary

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)

Frequency of Relapses in Patients Treated for up to 24 Months

24 months · Confirmed relapse per year

Fingolimod	0.122 Confirmed relapse per year
Interferon Beta-1a	0.675 Confirmed relapse per year

p-value	<0.001

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский